Point72 Hong Kong LTD Viking Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $48,441 - $72,317	-22,958 Reduced 99.81%	44 $0
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $44,124 - $71,775	14,708 Added 177.33%	23,002 $69,000
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $38,152 - $55,735	8,294 New	8,294 $38,000
Q1 2021 May 17, 2021	SELL	$5.74 - $9.67 $12,392 - $20,877	-2,159 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $2,718 - $3,442	513 Added 31.17%	2,159 $12,000
Q3 2020 Nov 16, 2020	BUY	$5.73 - $8.11 $9,431 - $13,349	1,646 New	1,646 $10,000
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $18,562 - $24,372	-2,834 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $21,736 - $30,125	2,834 New	2,834 $24,000
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $1,637 - $2,147	-216 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $1,546 - $3,501	216 New	216 $2,000
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $72,381 - $146,628	-7,462 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $28,952 - $95,065	7,462 New	7,462 $71,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.95B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.